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Summary
Background Population-based cancer survival estimates provide valuable insights into the effectiveness of cancer 
services and can reflect the prospects of cure. As part of the second phase of the International Cancer Benchmarking 
Partnership (ICBP), the Cancer Survival in High-Income Countries (SURVMARK-2) project aims to provide a 
comprehensive overview of cancer survival across seven high-income countries and a comparative assessment of 
corresponding incidence and mortality trends.
Methods In this longitudinal, population-based study, we collected patient-level data on 3·9 million patients with cancer 
from population-based cancer registries in 21 jurisdictions in seven countries (Australia, Canada, Denmark, Ireland, 
New Zealand, Norway, and the UK) for seven sites of cancer (oesophagus, stomach, colon, rectum, pancreas, lung, and 
ovary) diagnosed between 1995 and 2014, and followed up until Dec 31, 2015. We calculated age-standardised net 
survival at 1 year and 5 years after diagnosis by site, age group, and period of diagnosis. We mapped changes in incidence 
and mortality to changes in survival to assess progress in cancer control.
Findings In 19 eligible jurisdictions, 3 764 543 cases of cancer were eligible for inclusion in the study. In the 19 included 
jurisdictions, over 1995–2014, 1-year and 5-year net survival increased in each country across almost all cancer types, 
with, for example, 5-year rectal cancer survival increasing more than 13 percentage points in Denmark, Ireland, and 
the UK. For 2010–14, survival was generally higher in Australia, Canada, and Norway than in New Zealand, Denmark, 
Ireland, and the UK. Over the study period, larger survival improvements were observed for patients younger than 
75 years at diagnosis than those aged 75 years and older, and notably for cancers with a poor prognosis (ie, oesophagus, 
stomach, pancreas, and lung). Progress in cancer control (ie, increased survival, decreased mortality and incidence) 
over the study period was evident for stomach, colon, lung (in males), and ovarian cancer.
Interpretation The joint evaluation of trends in incidence, mortality, and survival indicated progress in four of the 
seven studied cancers. Cancer survival continues to increase across high-income countries; however, international 
disparities persist. While truly valid comparisons require differences in registration practice, classification, and coding 
to be minimal, stage of disease at diagnosis, timely access to effective treatment, and the extent of comorbidity are 
likely the main determinants of patient outcomes. Future studies are needed to assess the impact of these factors to 
further our understanding of international disparities in cancer survival.
Funding Canadian Partnership Against Cancer; Cancer Council Victoria; Cancer Institute New South Wales; Cancer 
Research UK; Danish Cancer Society; National Cancer Registry Ireland; The Cancer Society of New Zealand; National 
Health Service England; Norwegian Cancer Society; Public Health Agency Northern Ireland, on behalf of the Northern 
Ireland Cancer Registry; The Scottish Government; Western Australia Department of Health; and Wales Cancer 
Network.
Copyright © This is an Open Access article published under the CC BY-NC-ND 3.0 IGO license which permits 
unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. In any 
use of this article, there should be no suggestion that WHO endorses any specific organisation, products or services. 
The use of the WHO logo is not permitted. This notice should be preserved along with the article’s original URL.
Introduction
The International Cancer Benchmarking Partnership 
(ICBP) is a global, multidisciplinary partnership of 
clinicians, academics, and policy makers seeking to 
understand how and why cancer survival differs across 
countries that have high-quality cancer registries and 
universal access to, and comparable expenditure on, 
health care.1 The first phase of ICBP resulted in a series 
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of studies that have sought to comprehensively 
understand and address international cancer survival 
variations, including an assessment of four cancers over 
the period 1995–2007 in six countries.2 During the second 
phase of ICBP, the Cancer Survival in High-Income 
Countries (SURVMARK-2) project3 was established to 
further explore the underlying reasons for observed 
survival differences across an expanded set of cancer 
types, with a focus on indicators that inform clinical 
practice and public health, and engagement with a 
multidisciplinary group of collaborators and stakeholders.
Several studies in high-income countries have shown 
consistent improvements in cancer survival over the past 
two decades, yet survival differences between countries 
have been a permanent feature for most cancer sites and 
continue to persist, albeit to varying extents.2,4,5 These 
differences have been interpreted, and in some cases 
validated, as partly reflecting variations in progress in 
advancing cancer services, motivating policy reforms 
across countries.1 However, evolving cancer control plans 
need to be assessed not only in light of improvements in 
survival, but also taking into account trends in incidence 
and mortality to better understand the underlying bio-
logical, epidemiological, and clinical processes involved.
Benchmarking international variations in cancer 
survival remains a highly complex exercise given the 
numerous potential factors that might explain observed 
variations. In addition to factors that directly affect 
patient outcomes, such as stage at diagnosis and 
treatment,6–9 survival can also be influenced by differ-
ences in how cancer cases are registered and classified.10 
Additionally, national and subnational variability in 
factors linked to the underlying health systems, cancer 
policy, and clinical practice could all be important 
drivers. As such, public awareness and beliefs about 
cancer are considered to have less of an influence on 
international differences in survival.11,12
This initial paper from ICBP SURVMARK-2 aims to 
describe current patterns and recent trends in population-
based survival, incidence, and mortality for seven can-
cers in seven countries using data from high-quality, 
population-based cancer registries, and to generate 
hypotheses with regards to the drivers of these trends.
Methods
Data collection
In this longitudinal, population-based study, we obtained 
patient-level data on primary cancers of the oesophagus, 
stomach, colon, rectum, liver, pancreas, lung, and ovary 
from 21 population-based cancer registries covering 
21 jurisdictions in seven countries: Australia (New 
South Wales, Victoria, and Western Australia), Canada 
(Alberta, British Columbia, Manitoba, New Brunswick, 
Newfoundland and Labrador, Nova Scotia, Ontario, Prince 
Research in context
Evidence before this study
We searched PubMed, with no language restrictions, on 
Jan 15, 2019, for studies containing one or more of the terms 
“survival”, “cancer”, “incidence”, “mortality”, and “trends” to 
identify relevant population-based studies assessing survival 
alongside incidence or mortality, or both, for one or more of 
the following cancer types: oesophagus, stomach, colon, 
rectum, pancreas, lung, and ovary. Benchmarking international 
population-based cancer survival differences has proven to be a 
highly complex but crucial way to develop and assess 
early-detection strategies, the quality of clinical care, and the 
management of cancer patients. Although consistent 
improvements in cancer survival have been reported in the 
past two decades, survival differences appear to persist for 
most cancer sites, motivating policy reforms in specific 
countries.
Added value of this study
As part of the second phase of the International Cancer 
Benchmarking Partnership (ICBP), the Cancer Survival in 
High-Income Countries (SURVMARK-2) benchmarks 1-year and 
5-year net survival by age and period of diagnosis for seven 
cancers (oesophagus, stomach, colon, rectum, pancreas, lung, 
and ovary) in seven countries (Australia, Canada, Denmark, 
Ireland, New Zealand, Norway, and the UK), using data from 
21 high-quality population-based cancer registries for the 
period 1995–2014, with follow-up until Dec 31, 2015. 
High levels of data scrutiny, close interactions with a 
multidisciplinary group of data providers, epidemiologists, 
and clinicians, and efforts to extend the set of relevant indicators 
make this study unique. This report builds on previous studies by 
providing a combined assessment of trends in incidence, 
mortality, and survival to measure successes in cancer control.
Implications of all the available evidence
We found that cancer survival continues to improve across 
high-income countries, although international disparities 
persist even for cancers with poor prognoses. Progress likely 
stems from earlier diagnosis and improved treatment, 
alongside policy reforms that have ensured improved pathways 
to diagnosis and treatment. The favourable 20-year stomach, 
colon, lung (males), and ovarian cancer incidence and mortality 
trends are probably attributable to the delivery of interventions 
across the spectrum of cancer control, including effective cancer 
prevention and treatment. Although differences in registration 
practice, classification, and coding are unlikely to explain the 
variations reported here, ICBP SURVMARK-2 seeks to quantify 
the effect of specific registration-related factors on 
country-specific cancer survival, including definitions of date of 
diagnosis, and how death certificates (as the initial source of 
registration), are dealt with, building on previous assessments. 
Innovative measures of cancer survival will be included in 
forthcoming papers and made publicly available via an online 
tool to facilitate the next generation of benchmarking studies.
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Edward Island, Quebec, and Saskatchewan), Denmark, 
Ireland, New Zealand, Norway, and the UK (England, 
Scotland, Wales, and Northern Ireland). Cancers diag-
nosed in the period 1995–2014 with follow-up until 
Dec 31, 2015, were selected and coded according to the 
following rubrics of the tenth revision of the International 
Classification of Diseases (ICD-10): oesophagus (C15), 
stomach (C16), colon (C18–19), rectum (C20), liver (C22), 
pancreas (C25), lung (C34), and ovary including perito-
neum and fallopian tube in females only (C48.1–2, C56, 
C57.0). Only invasive tumours (behaviour code 3) were 
included, and all borderline ovarian cancers were excluded 
(third revision of the ICD for Oncology codes 8442, 8451, 
8462, 8472, and 8473).
We collected patient-level information on the following 
variables: histology, morphology, basis of diagnosis, stage 
at diagnosis, and treatment. While 18 registries provided 
full dates of diagnosis and vital status, three provided 
survival time in days (British Columbia, Norway, and 
Scotland). Three registries could not provide incidence 
data for the full 20-year period (data were available for 
New South Wales for 1995–2012, Ireland for 1995–2013, 
and Quebec for 2000–2011). Given our focus on temporal 
comparisons of patients diagnosed during 1995–2014, 
data from two Canadian jurisdictions were excluded: 
Quebec, because they only had data available from 2000, 
and Newfoundland and Labrador, because linkage of 
registered cases to vital status information was not 
systematically carried out before 2005. Hence, 19 juris -
dictions were included in our analysis. Given the 
complexities in registration, classifi cation, and differen-
tiation of primary and secondary tumours of the liver, 
survival comparisons from this cancer site were not 
included here and will be presented in a separate paper.
Of all cases eligible for analysis in the 19 jurisdictions, 
we excluded cases diagnosed on the basis of death 
certificate only or at autopsy; those with invalid or 
missing dates, age, or non-malignant behaviour; those in 
patients aged younger than 15 years or older than 99 years 
at diagnosis; and second or higher order cancers at the 
same site (ie, if a patient had two colon cancers during 
the study period, only the first would be included).
National estimates of cancer mortality for the period 
1995–2014 were obtained from the following sources: 
Australian Bureau of Statistics (all Australian juris-
dictions), Statistics Canada (all Canadian jurisdictions), 
the Danish Health Data Authority, Central Statistics 
Office Ireland, Norwegian Institute of Public Health, 
New Zealand Ministry of Health, Office for National 
Statistics (Wales and England, UK), National Records of 
Scotland, and the General Registrar’s Office for Northern 
Ireland. All data were submitted through a secured portal 
at the International Agency for Research on Cancer 
(IARC) and the data were handled according to applicable 
data protection and privacy laws, rules, and regulations. 
Ethical approval was obtained from each participating 
registry and from the IARC Ethics Committee.
Quality control
We subjected each registry dataset to several data quality 
assessments, which included scrutinising data for specific 
anomalies, such as instances of negative survival duration 
(date of death occurring before date of diagnosis); out-of-
range dates of diagnosis or dates of death, or both; and 
invalid vital status codes. Additionally, every case was 
checked for consistency in terms of patient sex and sex-
specific cancer site; site and morphology; age and site; age 
and morphology; and age, site, and morphology. We 
constructed tables including data quality indicators and 
communicated these to the registries and any issues 
identified were followed up and discussed in detail via 
one-to-one interviews between the investigators and 
registry staff. Interviews with key staff at the registries 
were carried out at an early phase of the study (in parallel 
with the call for data) to inform local case finding and 
ascertainment mechanisms, linkage to vital statistics, and 
coding and classification practices. Revised datasets were 
submitted by the registries when necessary. Data from all 
jurisdictions were subsequently harmonised according 
to international standards. The overall flow of data, 
including checks and exclusions, are in the appendix 
(p 25).
Statistical analysis
We calculated net survival to estimate population-based 
cancer survival, which was taken as the survival of 
patients in a defined resident population if cancer was 
the only possible cause of death. We present net survival 
with accompanying 95% CIs and used this metric to 
ensure fair comparisons across groups in which the 
chance of dying of other diseases varies. Net survival was 
estimated for each primary site in each jurisdiction, and 
for the Canadian, Australian, and UK jurisdictions 
combined. Follow-up was available until Dec 31, 2015, for 
all patients except for those in Ontario, where follow-up 
was limited to Dec 31, 2014.
We obtained background mortality in the general 
population of each jurisdiction from lifetables of all-
cause mortality by sex, single year of age, and calendar 
year of death during 1995–2014. Complete lifetables 
were available for all but one juris diction (Prince 
Edward Island, Canada), for which we used a Poisson 
model to interpolate 1-year intervals from an abridged 
(5-year) lifetable. We imputed missing adjacent years 
(a maximum of 2 years) using the last observation 
carried forward method. We supplemented missing 
years or ages, or both,in the lifetables for New Zealand 
with data from the Human Mortality Database.
We calculated survival estimates at 1 year and 5 years 
after diagnosis by age group (<75 years vs ≥75 years), time 
period of diagnosis (ie 1995–99, 2000–04, 2005–09, and 
2010–14), and cancer site for each jurisdiction using 
Pohar Perme estimators and the user-written Stata 
command stnet.13,14 We did age-standardised survival 
estimates using inter national cancer survival standard 
For International Association 
of Cancer Registries check and 
conversion program see 
http://www.iacr.com.fr/index.
php?option=com_content&view
=article&id=72:iarccrgtools&catid
=68&Itemid=445
For recommendations by the 
European Network of Cancer 
Registeries see https://www.
encr.eu/working-groups-and-
recommendations
See Online for appendix
For the Human Mortality 
Database see www.mortality.org
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weights.15 We used the cohort approach for 1995–99, 
2000–04, and 2005–09, and we used the period approach 
for patients diagnosed in 2010–14 (period window: 
2012–14). In secondary analyses, we included cases that 
were diagnosed on the basis of death certificate or 
autopsy under the assumption that survival equalled 
1 day. This assumption represents the most extreme 
scenario to assess the potential maximum (unrealistic) 
effect of inclusion of these cases.
We calculated trends in age-standardised cancer inci-
dence and mortality for patients aged 25 years and older 
using the age-truncated World Standard Population data16 
and expressed per 100 000 person-years. For incidence 
and mortality estimates, slightly different codes were 
used for ovarian (includes only C56) and lung cancer 
(includes C33–34 for mortality). Because previous 
analyses have highlighted the importance of survival 
differences by age, we also presented the results by broad 
age groups at diagnosis (<75 years vs ≥75 years). 
Additionally, we did sex-specific analyses for lung cancer 
because of its distinct patterns and trends in incidence 
and mortality reflecting differences in smoking 
prevalence in males and females.
All analyses were carried out using Stata (version 14.2).
Cases 
identified
Exclusion criteria Cases included in 
analyses
Diagnosed on the basis 
of death certificate or 
autopsy
Quality control* Age <15 years or 
>99 years
Multiple cancers
Oesophagus
Australia 15 313 193 (1·25%) 77 (0·50%) 3 (0·02%) 9 (0·06%) 15 032 (98·16%)
Canada 23 560 309 (1·31%) 12 (0·05%) 7 (0·03%) 43 (0·18%) 23 189 (98·43%)
Denmark 8296 94 (1·13%) 0 2 (0·02%) 4 (0·05%) 8196 (98·79%)
Ireland 6471 107 (1·65%) 0 1 (0·02%) 7 (0·11%) 6356 (98·22%)
New Zealand 4943 33 (0·67%) 1 (0·02%) 2 (0·04%) 1 (0·02%) 4906 (99·25%)
Norway 3988 47 (1·18%) 0 1 (0·03%) 4 (0·10%) 3936 (98·70%)
UK 156 125 2137 (1·32%) 5 (<0·01%) 72 (0·05%) 115 (0·07%) 153 877 (98·56%)
Stomach
Australia 26 282 294 (1·12%) 124 (0·47%) 12 (0·05%) 51 (0·19%) 25 801 (98·17%)
Canada 43 370 607 (1·40%) 17 (0·04%) 10 (0·02%) 93 (0·21%) 42 643 (98·32%)
Denmark 10 745 159 (1·48%) 0 4 (0·04%) 3 (0·03%) 10 579 (98·46%)
Ireland 9413 276 (2·93%) 0 1 (0·01%) 18 (0·19%) 9118 (96·87%)
New Zealand 7635 69 (0·90%) 2 (0·03%) 7 (0·09%) 1 (0·01%) 7556 (98·97%)
Norway 11 255 134 (1·19%) 0 4 (0·04%) 18 (0·16%) 11 099 (98·61%)
UK 170 448 3454 (1·94%) 16 (0·01%) 94 (0·06%) 216 (0·13%) 166 812 (97·87%)
Colon
Australia 126 281 1291 (1·02%) 584 (0·46%) 95 (0·08%) 4244 (3·36%) 120 067 (95·08%)
Canada 210 013 2321 (1·11%) 93 (0·04%) 85 (0·04%) 3433 (1·63%) 204 081 (97·18%)
Denmark 51 821 444 (0·86%) 0 24 (0·05%) 447 (0·86%) 50 906 (98·23%)
Ireland 29 026 618 (2·13%) 1 (<0·01%) 11 (0·04%) 852 (2·94%) 27 544 (94·89%)
New Zealand 40 408 245 (0·61%) 1 (<0·01%) 13 (0·03%) 58 (0·14%) 40 091 (99·22%)
Norway 48 748 540 (1·11%) 116 (0·24%) 23 (0·05%) 824 (1·69%) 47 245 (96·92%)
UK 540 800 8955 (1·60%) 45 (0·01%) 638 (0·12%) 14 249 (2·64%) 517 231 (95·64%)
Rectum
Australia 45 562 213 (0·47%) 102 (0·22%) 8 (0·02%) 1195 (2·62%) 44 044 (96·67%)
Canada 66 449 416 (0·63%) 22 (0·03%) 20 (0·03%) 1075 (1·62%) 64 916 (97·69%)
Denmark 26 173 172 (0·66%) 0 7 (0·03%) 290 (1·11%) 25 704 (98·21%)
Ireland 11 235 121 (1·08%) 0 2 (0·02%) 202 (1·80%) 10 910 (97·11%)
New Zealand 13 369 65 (0·49%) 3 (0·02%) 8 (0·06%) 243 (1·82%) 13 050 (97·61%)
Norway 20 557 98 (0·48%) 0 7 (0·03%) 486 (2·36%) 19 966 (97·13%)
UK 210 073 2214 (1·02%) 14 (0·01%) 89 (0·04%) 3232 (1·54%) 204 586 (97·39%)
(Table 1 continues on next page)
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Role of the funding source
The funders had a role in writing of the report and had 
no role in study design, data collection, data analysis, or 
data interpretation. MA, MJR, AB, and IS had access to 
the raw data. The corresponding author had full access to 
all the data in the study and had final responsibility for 
the decision to submit for publication.
Results
Of the 3 890 934 cancer cases that were eligible for 
analysis in the 19 jurisdictions, 126 391 (3·2%) were 
excluded due to the cancer diagnosis only being based 
on a death certificate or at autopsy (77 578 [2·0%]); invalid 
or missing dates, age, or non-malignant behaviour of the 
cancer (4471 [0·1%]); the patient being younger than 
15 years or older than 99 years at diagnosis (2438 [<0·1%]); 
and second or higher order cancers being present at the 
same site as the primary cancer (41 904 [1·1%]). Hence, 
3 764 543 (96·8%) of eligible cancer cases were included 
in the analyses (table 1; appendix p 25).
In the most recent 5-year period of diagnosis (2010–14), 
the highest 1-year survival for most cancer sites was in 
Australia, followed by Canada and Norway (appendix 
pp 11–12). The lowest 1-year survival was observed for 
stomach, colon, rectal, and lung cancer in the UK; and 
for oesophageal cancer in Canada, pancreatic cancer in 
New Zealand, and ovarian cancer in Ireland. Similar 
patterns were observed for 5-year survival (table 2), with 
consistently higher survival in Australia than in the other 
countries, except for lung (Canada) and ovarian cancer 
(Norway), and lower survival in the UK, except for 
oesophageal (Denmark) and ovarian cancer (Ireland). 
Inclusion of cases that were diagnosed on the basis of 
death certificate or autopsy in secondary analyses did not 
substantially change the results (appendix pp 23–24). 
Using this scenario, 5-year survival estimates were 
Cases 
identified
Exclusion criteria Cases included in 
analyses
Diagnosed on the basis 
of death certificate or 
autopsy
Quality control* Age <15 years or 
>99 years
Multiple cancers
(Continued from previous page)
Pancreas
Australia 29 636 1054 (3·56%) 599 (2·02%) 19 (0·06%) 5 (0·02%) 27 959 (94·34%)
Canada 53 922 2116 (3·92%) 42 (0·08%) 34 (0·06%) 12 (0·02%) 51 718 (95·91%)
Denmark 16 676 411 (2·46%) 0 3 (0·02%) 1 (0·01%) 16 261 (97·51%)
Ireland 7922 382 (4·82%) 0 2 (0·03%) 9 (0·11%) 7529 (95·04%)
New Zealand 8011 187 (2·33%) 2 (0·02%) 12 (0·15%) 0 7810 (97·49%)
Norway 13 188 487 (3·69%) 0 4 (0·03%) 3 (0·02%) 12 694 (96·25%)
UK 157 641 6623 (4·05%) 15 (0·01%) 110 (0·07%) 70 (0·04%) 151 064 (95·83%)
Lung
Australia 119 915 2826 (2·36%) 1234 (1·03%) 36 (0·03%) 727 (0·61%) 115 092 (95·98%)
Canada 304 284 6818 (2·24%) 175 (0·06%) 55 (0·02%) 2445 (0·80%) 294 791 (96·88%)
Denmark 79 731 1591 (2·00%) 0 7 (0·01%) 140 (0·18%) 77 993 (97·82%)
Ireland 35 659 1200 (3·37%) 4 (0·01%) 7 (0·02%) 306 (0·86%) 34 142 (95·75%)
New Zealand 35 666 720 (2·02%) 2 (0·01%) 8 (0·02%) 14 (0·04%) 34 922 (97·91%)
Norway 47 872 938 (1·96%) 0 8 (0·02%) 321 (0·67%) 46 605 (97·35%)
UK 821 586 22 709 (2·63%) 667 (0·08%) 209 (0·03%) 5567 (0·68%) 793 535 (96·59%)
Ovary
Australia 18 004 275 (1·53%) 119 (0·66%) 72 (0·40%) 56 (0·31%) 17 482 (97·10%)
Canada 39 030 546 (1·40%) 11 (0·03%) 153 (0·39%) 107 (0·27%) 38 213 (97·91%)
Denmark 11 810 105 (0·89%) 0 17 (0·14%) 64 (0·54%) 11 624 (98·43%)
Ireland 6517 147 (2·26%) 1 (0·02%) 15 (0·23%) 22 (0·34%) 6332 (97·16%)
New Zealand 5796 47 (0·81%) 1 (0·02%) 29 (0·50%) 12 (0·21%) 5707 (98·46%)
Norway 9960 116 (1·16%) 16 (0·16%) 25 (0·25%) 36 (0·36%) 9767 (98·06%)
UK 129 748 2655 (1·98%) 348 (0·27%) 363 (0·28%) 574 (0·44%) 125 892 (97·03%)
Data are n or n (%). Proportions are calculated using the number of cases identified as the denominator. *Data inconsistencies included invalid age, missing or incomplete 
dates, tumours with non-malignant behaviour, and tumours with invalid morphological or topographical codes.
Table 1: Number of cancer cases identified and included in analysis 1995–2014 by cancer site and country
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Australia* Canada† Denmark Ireland‡ New Zealand Norway UK§
Oesophagus
1995–99 18·3% (16·9–19·9) 13·5% (12·4–14·6) 5·1% (3·9–6·6) 10·9% (9·1–12·9) 13·6% (11·2–16·1) 8·7% (6·7–11·0) 8·6% (8·2–9·0)
2000–04 17·8% (16·5–19·2) 14·2% (13·2–15·3) 8·6% (7·2–10·1) 12·8% (11·0–14·7) 11·6% (9·6–13·9) 9·0% (6·8–11·6) 11·4% (11·0–11·8)
2005–09 18·4% (17·1–19·8) 14·8% (13·8–15·8) 10·5% (9·0–12·0) 17·2% (15·3–19·2) 14·3% (12·1–16·6) 13·2% (10·8–15·7) 13·8% (13·4–14·2)
2010–14 23·5% (21·6–25·4) 16·3% (15·1–17·5) 14·7% (12·1–17·5) 21·9% (19·3–24·5) 16·9% (14·3–19·7) 19·4% (16·5–22·5) 16·2% (15·7–16·7)
Absolute change 5·2 2·8 9·6 11·0 3·3 10·7 7·6
Stomach
1995–99 25·7% (24·6–26·9) 21·5% (20·6–22·4) 14·0% (12·5–15·7) 17·3% (15·5–19·1) 21·3% (19·2–23·4) 21·3% (19·5–23·1) 14·1% (13·7–14·4)
2000–04 28·1% (26·9–29·3) 24·1% (23·2–25·1) 15·2% (13·7–16·9) 18·5% (16·7–20·4) 23·7% (21·6–25·9) 22·0% (20·2–23·9) 16·0% (15·6–16·5)
2005–09 29·2% (28·0–30·4) 26·2% (25·3–27·1) 15·7% (14·2–17·3) 22·0% (20·2–23·9) 24·0% (21·9–26·2) 25·1% (23·1–27·2) 19·0% (18·5–19·5)
2010–14 32·8% (31·3–34·3) 29·8% (28·6–30·9) 22·6% (20·6–24·8) 28·4% (26·1–30·9) 24·5% (22·1–27·0) 26·9% (24·6–29·3) 20·8% (20·2–21·4)
Absolute change 7·1 8·3 8·6 11·1 3·2 5·6 6·7
Colon
1995–99 59·6% (58·9–60·3) 57·9% (57·3–58·4) 49·1% (47·9–50·3) 50·0% (48·5–51·6) 59·3% (58·0–60·6) 55·7% (54·4–57·0) 47·0% (46·7–47·4)
2000–04 63·5% (62·8–64·1) 61·3% (60·7–61·8) 53·2% (52·0–54·3) 52·7% (51·3–54·2) 60·3% (59·1–61·5) 58·0% (56·8–59·1) 51·0% (50·6–51·3)
2005–09 67·1% (66·5–67·8) 65·4% (64·9–65·9) 57·5% (56·4–58·6) 58·0% (56·7–59·3) 61·6% (60·4–62·8) 62·2% (61·1–63·3) 55·3% (55·0–55·7)
2010–14 70·8% (70·0–71·5) 66·8% (66·2–67·4) 65·7% (64·5–66·9) 61·8% (60·2–63·3) 62·1% (60·8–63·4) 65·4% (64·2–66·5) 58·9% (58·6–59·3)
Absolute change 11·2 8·9 16·6 11·8 2·8 9·7 11·9
Rectum
1995–99 59·1% (57·9–60·3) 57·5% (56·5–58·6) 48·1% (46·4–49·8) 47·6% (45·1–50·0) 56·3% (54·0–58·6) 57·3% (55·5–59·1) 47·8% (47·3–48·4)
2000–04 64·1% (63·0–65·1) 61·6% (60·6–62·5) 54·0% (52·3–55·7) 51·0% (48·8–53·2) 59·7% (57·5–61·8) 61·5% (59·8–63·2) 53·0% (52·4–53·5)
2005–09 68·5% (67·5–69·5) 65·4% (64·5–66·2) 60·7% (59·2–62·1) 57·1% (54·9–59·2) 62·4% (60·4–64·4) 65·4% (63·7–67·0) 57·0% (56·5–57·5)
2010–14 70·8% (69·6–72·0) 67·0% (66·0–68·1) 69·1% (67·4–70·8) 62·4% (59·9–64·9) 65·4% (63·1–67·5) 68·8% (66·9–70·6) 62·1% (61·5–62·6)
Absolute change 11·7 9·5 21·0 14·8 9·1 11·5 14·3
Pancreas
1995–99 6·4% (5·7–7·2) 7·0% (6·4–7·5) 3·2% (2·5–4·0) 5·6% (4·4–7·0) 8·8% (7·3–10·6) 4·4% (3·5–5·5) 3·3% (3·0–3·5)
2000–04 7·8% (7·1–8·6) 7·8% (7·2–8·4) 3·8% (3·1–4·6) 5·9% (4·7–7·3) 6·9% (5·6–8·5) 4·7% (3·8–5·7) 4·0% (3·7–4·3)
2005–09 9·2% (8·5–10·0) 9·6% (9·1–10·2) 5·7% (4·9–6·5) 7·0% (5·8–8·4) 7·3% (6·1–8·7) 5·9% (5·0–7·0) 5·5% (5·2–5·8)
2010–14 14·6% (13·5–15·7) 11·1% (10·4–11·8) 9·6% (8·5–10·9) 9·6% (7·8–11·6) 8·2% (6·8–9·7) 9·9% (8·5–11·4) 7·9% (7·6–8·3)
Absolute change 8·2 4·1 6·4 4·0 –0·6 5·5 4·6
Lung
1995–99 13·3% (12·9–13·8) 15·4% (15·1–15·7) 8·2% (7·7–8·7) 9·3% (8·5–10·1) 11·5% (10·7–12·4) 10·8% (10·1–11·6) 7·2% (7·0–7·3)
2000–04 14·9% (14·5–15·4) 16·0% (15·7–16·4) 9·7% (9·2–10·2) 10·1% (9·3–10·9) 10·9% (10·2–11·7) 11·8% (11·1–12·5) 8·3% (8·2–8·5)
2005–09 17·3% (16·8–17·8) 18·5% (18·2–18·8) 12·4% (11·9–13·0) 13·4% (12·7–14·2) 11·9% (11·1–12·7) 15·4% (14·7–16·2) 10·0% (9·8–10·2)
2010–14 21·4% (20·8–22·0) 21·7% (21·3–22·2) 18·9% (18·1–19·6) 19·8% (18·7–20·9) 15·5% (14·5–16·5) 20·4% (19·4–21·4) 14·7% (14·5–15·0)
Absolute change 8·1 6·3 10·7 10·5 4·0 9·6 7·5
Ovary
1995–99 35·5% (33·9–37·1) 35·5% (34·4–36·7) 32·0% (30·0–33·9) 27·8% (25·2–30·5) 31·9% (29·0–34·8) 37·0% (34·8–39·3) 27·3% (26·8–27·9)
2000–04 36·2% (34·6–37·8) 36·4% (35·3–37·5) 34·2% (32·3–36·1) 29·6% (27·2–32·1) 33·5% (30·7–36·4) 40·6% (38·4–42·8) 29·0% (28·4–29·5)
2005–09 40·1% (38·6–41·7) 39·8% (38·7–40·9) 38·3% (36·3–40·2) 31·1% (28·7–33·5) 32·7% (30·0–35·4) 41·3% (39·1–43·5) 32·1% (31·6–32·7)
2010–14 43·2% (41·3–45·1) 40·3% (39·0–41·6) 42·1% (39·8–44·5) 36·0% (33·0–38·9) 36·3% (33·3–39·4) 46·2% (43·6–48·8) 37·1% (36·5–37·8)
Absolute change 7·7 4·8 10·1 8·2 4·4 9·2 9·8
Data are 5-year age-standardised net survival estimate (95% CI) and absolute change in percentage points. Absolute change is between 1995–99 and 2010–14. *Australia includes New South Wales (1995–2012), 
Victoria, and Western Australia. †Canada includes Alberta, British Columbia, Manitoba, New Brunswick, Nova Scotia, Ontario, Prince Edward Island, and Saskatchewan. ‡Ireland (1995–2013). §The UK includes its 
four consituents countries: England, Scotland, Wales, and Northern Ireland.
Table 2: Age-standardised 5-year net survival by cancer site, country, and period of diagnosis
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reduced by a maximum of 0·6 percentage points across 
all countries in 2010–14.
Differences in 1-year and 5-year survival across 
jurisdictions within countries were observed over time, 
with large variations for 2010–14 found in 5-year survival 
for oesophageal cancer in Australia (26% in Victoria vs 
19% in New South Wales), pancreatic cancer in Canada 
(13% in Manitoba vs 7% in Nova Scotia), and colon cancer 
in the UK (63% in Northern Ireland vs 57% in Wales; 
appendix pp 17–22).
Cancer survival increased in all seven countries over 
the 20-year study period, and improvements, at least in 
relative terms, were most substantial for the cancer sites 
associated with a generally poor prognosis (oesophagus, 
stomach, pancreas, and lung; figure 1), and for patients 
younger than 75 years at diagnosis (table 3; appendix 
pp 13–14). The most pronounced increases in 5-year 
survival were observed in Denmark for cancers of the 
colon, with a 16·6 percentage point absolute increase, 
and rectum, with a 21 percentage point absolute increase, 
between the 1995–99 and 2010–14 time periods (table 2, 
figure 1). The survival gap between countries narrowed 
over time for 1-year survival for all cancers except 
pancreatic cancer (because of substantial increases in 
survival in all countries), whereas for 5-year survival the 
survival gap only narrowed for oesophageal and rectal 
cancer (table 2). Differences in 5-year survival across 
countries were greater among patients aged 75 years and 
older than those younger than 75 years, and the survival 
gap widened for ovarian cancer in those older than 
75 years over the 20-year period but remained fairly stable 
for other cancer sites (tables 3 and 4).
Both 1-year and 5-year survival from oesophageal 
cancer increased substantially in all countries among 
patients diagnosed in the period 2010–14 compared with 
those diagnosed in 1995–99 (table 2; appendix pp 11–12). 
Comparing the periods 1995–99 and 2010–14, 5-year 
survival from oesophageal cancer increased by up to 
11 percentage points (in Ireland and Norway), which was 
more pronounced in those younger than 75 years at 
diagnosis (up to 14 percentage points in Ireland and 
Norway) than in those aged 75 years and older (up to 
7 percentage points in Denmark; tables 3 and 4). 
Although mortality has been stable or decreasing across 
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Figure 1: Age-standardised 5-year net survival by site, country, and period of diagnosis, 1995–2014
Age-standardised net survival is for patients aged 15–99 years at diagnosis. Beginning of arrow denotes estimates for 1995–99 and arrow heads from left to right 
refer to 2000–04, 2005–09, and 2010–14 estimates. Australia includes New South Wales (1995–2012), Victoria, and Western Australia; Canada includes Alberta, 
British Columbia, Manitoba, New Brunswick, Nova Scotia, Ontario, Prince Edward Island, and Saskatchewan; Ireland (1995–2013); the UK includes its four constituent 
countries: England, Scotland, Wales, and Northern Ireland; all other countries with national data (1995–2014).
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Australia* Canada† Denmark Ireland‡ New Zealand Norway UK§
Oesophagus
1995–99 21·4% (19·5–23·4) 15·4% (14·0–16·8) 6·6% (5·1–8·3) 12·9% (10·6–15·4) 15·6% (12·6–19·0) 10·0% (7·4–13·0) 10·7% (10·2–11·2)
2000–04 21·1% (19·3–22·9) 16·5% (15·2–17·9) 10·4% (8·6–12·4) 15·7% (13·3–18·2) 15·0% (12·1–18·1) 11·3% (8·3–14·9) 14·2% (13·7–14·8)
2005–09 21·5% (19·7–23·3) 16·9% (15·6–18·2) 13·2% (11·3–15·2) 20·8% (18·3–23·4) 17·8% (14·8–21·0) 17·0% (13·9–20·4) 17·1% (16·6–17·7)
2010–14 26·9% (24·5–29·4) 18·4% (17·0–20·0) 17·3% (14·0–20·9) 27·0% (23·7–30·5) 20·9% (17·4–24·7) 24·4% (20·6–28·3) 19·6% (19·0–20·3)
Absolute change 5·5 3·0 10·7 14·1 5·3 14·4 8·9
Stomach
1995–99 29·1% (27·6–30·6) 23·3% (22·1–24·4) 16·3% (14·4–18·3) 19·7% (17·5–22·0) 23·4% (20·8–26·0) 23·5% (21·3–25·8) 16·5% (16·0–17·0)
2000–04 31·7% (30·2–33·2) 26·8% (25·7–28·0) 17·7% (15·7–19·7) 21·0% (18·7–23·3) 27·2% (24·6–30·0) 25·2% (22·8–27·6) 18·9% (18·3–19·5)
2005–09 32·9% (31·3–34·4) 28·6% (27·4–29·7) 18·7% (16·8–20·6) 26·4% (24·0–28·8) 27·0% (24·4–29·7) 28·3% (25·7–30·9) 22·7% (22·0–23·3)
2010–14 37·4% (35·5–39·3) 32·9% (31·5–34·3) 25·9% (23·3–28·5) 32·8% (29·8–35·8) 29·1% (26·1–32·3) 30·5% (27·6–33·5) 24·0% (23·3–24·8)
Absolute change 8·3 9·6 9·6 13·1 5·7 7·0 7·5
Colon
1995–99 62·1% (61·3–62·9) 59·0% (58·3–59·7) 50·2% (48·8–51·6) 52·4% (50·6–54·2) 59·4% (58·0–60·8) 57·7% (56·2–59·2) 50·6% (50·1–51·0)
2000–04 66·3% (65·5–67·0) 63·2% (62·6–63·8) 54·0% (52·6–55·3) 55·7% (54·0–57·3) 61·0% (59·6–62·4) 60·3% (58·8–61·7) 54·7% (54·3–55·2)
2005–09 69·8% (69·1–70·5) 67·9% (67·4–68·5) 60·2% (58·9–61·4) 62·0% (60·5–63·5) 62·9% (61·5–64·3) 64·1% (62·8–65·4) 59·6% (59·2–60·0)
2010–14 73·3% (72·5–74·1) 69·6% (69·0–70·3) 66·4% (65·0–67·8) 66·5% (64·7–68·2) 64·5% (62·9–66·0) 67·5% (66·1–68·8) 64·2% (63·7–64·6)
Absolute change 11·2 10·6 16·2 14·1 5·1 9·8 13·6
Rectum
1995–99 62·6% (61·3–63·8) 60·8% (59·6–61·9) 51·3% (49·4–53·2) 49·6% (47·0–52·2) 58·5% (56·0–61·0) 61·4% (59·3–63·5) 53·0% (52·4–53·7)
2000–04 68·3% (67·1–69·4) 65·1% (64·1–66·1) 57·9% (56·1–59·7) 56·6% (54·1–59·0) 62·9% (60·5–65·1) 64·9% (63·0–66·8) 58·5% (57·9–59·1)
2005–09 72·6% (71·5–73·6) 69·8% (68·9–70·7) 65·4% (63·8–67·0) 63·4% (61·1–65·7) 66·6% (64·4–68·7) 69·7% (67·9–71·5) 63·3% (62·7–63·9)
2010–14 75·0% (73·7–76·2) 72·9% (71·9–73·9) 72·6% (70·8–74·2) 67·9% (65·3–70·3) 69·3% (67·0–71·5) 72·1% (70·1–73·9) 68·5% (67·9–69·1)
Absolute change 12·4 12·1 21·3 18·3 10·8 10·7 15·5
Pancreas
1995–99 7·6% (6·7–8·7) 8·1% (7·4–8·9) 3·5% (2·7–4·5) 6·3% (4·8–8·2) 10·1% (8·1–12·4) 5·4% (4·2–6·8) 4·1% (3·7–4·4)
2000–04 9·4% (8·5–10·5) 9·4% (8·7–10·1) 4·9% (4·0–6·0) 6·3% (4·8–8·1) 8·2% (6·4–10·2) 5·7% (4·6–7·1) 5·1% (4·7–5·4)
2005–09 11·5% (10·5–12·5) 11·5% (10·7–12·2) 7·4% (6·4–8·6) 8·0% (6·5–9·8) 9·4% (7·7–11·3) 7·2% (5·8–8·6) 7·0% (6·6–7·4)
2010–14 18·1% (16·7–19·6) 14·1% (13·2–15·1) 12·2% (10·7–13·8) 11·7% (9·3–14·5) 11·2% (9·2–13·4) 12·3% (10·4–14·3) 10·0% (9·5–10·5)
Absolute change 10·5 6·0 8·7 5·4 1·1 6·9 5·9
Lung
1995–99 15·8% (15·2–16·4) 17·6% (17·2–18·0) 10·1% (9·5–10·7) 11·1% (10·1–12·1) 13·0% (11·9–14·0) 13·3% (12·4–14·2) 8·9% (8·7–9·1)
2000–04 17·3% (16·7–17·9) 18·3% (17·9–18·7) 11·7% (11·1–12·3) 12·2% (11·2–13·2) 12·9% (11·9–13·9) 14·3% (13·5–15·3) 10·2% (9·9–10·4)
2005–09 20·2% (19·6–20·8) 21·2% (20·8–21·6) 14·9% (14·2–15·6) 16·3% (15·3–17·4) 14·3% (13·3–15·3) 18·8% (17·8–19·8) 12·1% (11·9–12·3)
2010–14 24·6% (23·8–25·4) 24·8% (24·2–25·4) 21·3% (20·3–22·2) 23·5% (22·1–25·0) 18·8% (17·5–20·2) 23·9% (22·6–25·1) 17·4% (17·1–17·8)
Absolute change 8·8 7·2 11·2 12·4 5·8 10·6 8·5
Ovary
1995–99 43·3% (41·4–45·2) 41·2% (39·9–42·5) 37·3% (35·1–39·4) 33·6% (30·6–36·6) 37·4% (34·0–40·7) 44·5% (41·9–47·0) 32·9% (32·3–33·5)
2000–04 43·5% (41·6–45·4) 43·2% (42·0–44·5) 41·0% (38·8–43·1) 35·7% (32·8–38·5) 40·7% (37·3–44·0) 48·1% (45·6–50·7) 35·5% (34·9–36·2)
2005–09 48·0% (46·2–49·7) 47·7% (46·4–48·9) 45·6% (43·3–47·8) 38·9% (36·1–41·7) 40·8% (37·6–43·9) 49·2% (46·6–51·7) 39·2% (38·5–39·9)
2010–14 52·1% (50·0–54·1) 49·3% (47·8–50·8) 48·8% (46·2–51·3) 44·8% (41·4–48·2) 43·3% (39·8–46·8) 54·5% (51·7–57·3) 44·9% (44·1–45·7)
Absolute change 8·8 8·1 11·5 11·2 5·9 10·0 12·0
Data are 5-year age-standardised net survival estimate (95% CI) and absolute change in percentage points. Absolute change is between 1995–99 and 2010–14. *Australia includes New South Wales 
(1995–2012), Victoria, and Western Australia. †Canada includes Alberta, British Columbia, Manitoba, New Brunswick, Nova Scotia, Ontario, Prince Edward Island and Saskatchewan. ‡Ireland (1995–2013). 
§The UK includes its four consituents countries: England, Scotland, Wales, and Northern Ireland.
Table 3: Age-standardised 5-year net survival by cancer site, country and period of diagnosis in patients aged younger than 75 years
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Australia* Canada† Denmark Ireland‡ New Zealand Norway UK§
Oesophagus
1995–99 10·9% (8·9–13·1) 8·8% (7·0–10·8) 1·5% (0·4–4·6) 6·0% (3·6–9·2) 8·5% (5·2–12·6) 5·4% (2·8–9·4) 3·4% (3·0–3·8)
2000–04 9·8% (8·1–11·8) 8·6% (7·0–10·3) 4·1% (2·4–6·5) 5·7% (3·7–8·3) 3·4% (1·8–5·7) 3·4% (1·6–6·3) 4·4% (4·0–4·8)
2005–09 11·1% (9·4–13·0) 9·6% (8·1–11·3) 3·8% (2·2–6·1) 8·4% (6·0–11·3) 5·7% (3·7–8·3) 3·7% (1·8–6·6) 5·6% (5·1–6·0)
2010–14 14·8% (12·3–17·5) 10·9% (9·0–13·0) 8·4% (4·9–13·0) 9·4% (6·4–13·1) 6·7% (4·2–10·0) 6·0% (3·0–10·3) 7·5% (7·0–8·1)
Absolute change 3·9 2·1 6·9 3·4 –1·8 0·6 4·1
Stomach
1995–99 17·5% (15·6–19·5) 17·1% (15·5–18·8) 8·6% (6·2–11·4) 11·3% (8·4–14·6) 16·1% (12·8–19·8) 15·9% (13·5–18·4) 8·1% (7·6–8·6)
2000–04 19·3% (17·4–21·3) 17·5% (16·0–19·1) 9·3% (6·9–12·1) 12·5% (9·7–15·7) 15·2% (11·9–18·9) 14·2% (11·9–16·7) 9·0% (8·5–9·5)
2005–09 20·2% (18·2–22·1) 20·4% (18·8–22·0) 8·5% (6·4–11·0) 11·4% (9·0–14·2) 16·8% (13·4–20·6) 17·4% (14·6–20·5) 9·9% (9·4–10·5)
2010–14 21·5% (19·1–24·0) 22·1% (20·2–24·0) 14·7% (11·5–18·3) 17·8% (14·2–21·7) 13·1% (9·8–16·8) 18·1% (14·7–21·9) 12·6% (11·9–13·3)
Absolute change 4·0 5·0 6·1 6·5 –3·0 2·2 4·5
Colon
1995–99 53·4% (51·9–54·9) 55·1% (53·9–56·3) 46·4% (44·1–48·7) 44·3% (40·9–47·5) 59·0% (56·1–61·8) 50·8% (48·4–53·1) 38·4% (37·8–39·0)
2000–04 56·6% (55·2–57·9) 56·6% (55·5–57·6) 51·1% (48·8–53·4) 45·6% (42·7–48·5) 58·5% (56·0–61·0) 52·4% (50·2–54·5) 41·8% (41·2–42·4)
2005–09 60·6% (59·3–61·9) 59·2% (58·2–60·2) 50·9% (48·7–53·1) 48·2% (45·5–50·8) 58·4% (56·0–60·7) 57·7% (55·6–59·7) 45·0% (44·4–45·6)
2010–14 64·5% (63·0–66·1) 59·9% (58·7–61·1) 64·3% (61·6–66·8) 50·5% (47·4–53·6) 56·3% (53·8–58·7) 60·1% (57·7–62·4) 46·1% (45·5–46·8)
Absolute change 11·1 4·8 17·9 6·2 –2·7 9·3 7·7
Rectum
1995–99 50·8% (48·0–53·4) 49·7% (47·3–52·0) 40·3% (36·8–43·8) 42·6% (37·0–48·1) 51·0% (45·6–56·2) 47·2% (43·7–50·6) 35·1% (34·0–36·1)
2000–04 53·8% (51·4–56·2) 53·0% (50·8–55·1) 44·5% (40·8–48·0) 37·4% (32·6–42·2) 52·0% (47·0–56·8) 53·2% (49·7–56·6) 39·5% (38·5–40·5)
2005–09 58·6% (56·1–60·9) 54·6% (52·6–56·6) 49·1% (45·9–52·3) 41·5% (37·0–46·0) 52·2% (47·6–56·6) 54·9% (51·2–58·4) 41·7% (40·7–42·7)
2010–14 60·7% (57·7–63·5) 53·4% (51·1–55·6) 60·7% (56·7–64·5) 49·4% (43·7–54·9) 55·7% (50·3–60·7) 60·9% (56·5–65·0) 46·2% (45·0–47·3)
Absolute change 9·9 3·7 20·4 6·8 4·7 13·7 11·1
Pancreas
1995–99 3·3% (2·5–4·2) 4·0% (3·3–4·9) 2·3% (1·3–3·8) 3·8% (2·1–6·1) 5·6% (3·5–8·5) 2·1% (1·2–3·5) 1·3% (1·1–1·6)
2000–04 3·7% (2·9–4·7) 3·9% (3·2–4·6) 1·1% (0·6–2·0) 4·8% (3·1–7·1) 4·0% (2·3–6·3) 2·0% (1·2–3·1) 1·3% (1·1–1·5)
2005–09 3·8% (3·1–4·6) 5·1% (4·4–5·9) 1·4% (0·8–2·3) 4·5% (3·0–6·5) 2·2% (1·2–3·7) 3·0% (2·0–4·2) 1·9% (1·6–2·1)
2010–14 6·0% (4·9–7·2) 3·9% (3·2–4·6) 3·2% (2·0–4·8) 4·3% (2·6–6·5) 1·3% (0·6–2·4) 4·1% (2·7–5·8) 2·7% (2·4–3·1)
Absolute change 2·7 –0·1 0·9 0·5 –4·3 2·0 1·4
Lung
1995–99 7·3% (6·6–8·0) 10·0% (9·5–10·6) 3·4% (2·7–4·2) 5·0% (3·9–6·3) 7·9% (6·6–9·4) 4·8% (3·9–5·9) 3·0% (2·8–3·1)
2000–04 9·1% (8·5–9·8) 10·6% (10·1–11·1) 4·9% (4·1–5·8) 4·9% (3·9–5·9) 6·1% (5·1–7·3) 5·6% (4·7–6·6) 3·8% (3·6–4·0)
2005–09 10·3% (9·6–10·9) 11·9% (11·4–12·3) 6·5% (5·7–7·3) 6·3% (5·3–7·4) 6·1% (5·1–7·2) 7·1% (6·2–8·1) 4·9% (4·7–5·1)
2010–14 13·4% (12·5–14·3) 14·1% (13·5–14·7) 12·6% (11·3–13·8) 10·4% (8·9–12·0) 7·4% (6·2–8·8) 11·7% (10·4–13·1) 7·8% (7·5–8·1)
Absolute change 6·1 4·1 9·2 5·4 –0·5 6·9 4·8
Ovary
1995–99 16·4% (13·8–19·2) 21·6% (19·4–23·9) 19·0% (15·1–23·3) 13·7% (9·3–19·0) 18·4% (13·1–24·3) 18·8% (14·8–23·2) 13·7% (12·7–14·6)
2000–04 18·2% (15·7–20·9) 19·6% (17·8–21·6) 17·5% (14·1–21·2) 14·9% (10·7–19·7) 16·0% (11·7–21·1) 22·1% (18·4–26·0) 12·9% (12·1–13·8)
2005–09 20·9% (18·3–23·7) 20·6% (18·7–22·5) 20·4% (16·8–24·2) 12·0% (8·2–16·5) 12·8% (8·8–17·6) 22·0% (18·3–25·9) 14·8% (14·0–15·7)
2010–14 21·8% (18·5–25·2) 18·9% (16·7–21·1) 26·2% (21·7–30·9) 14·3% (10·2–19·1) 17·5% (12·2–23·5) 26·5% (21·7–31·6) 17·7% (16·7–18·9)
Absolute change 5·4 –2·7 7·2 0·6 –0·9 7·7 4·0
Data are 5-year age-standardised net survival estimate (95% CI) and absolute change in percentage points. Absolute change is between 1995–99 and 2010–14. *Australia includes New South Wales (1995–2012), 
Victoria, and Western Australia. †Canada includes Alberta, British Columbia, Manitoba, New Brunswick, Nova Scotia, Ontario, Prince Edward Island and Saskatchewan. ‡Ireland (1995–2013). §The UK includes its 
four consituents countries: England, Scotland, Wales, and Northern Ireland.
Table 4: Age-standardised 5-year net survival by cancer site, country and period of diagnosis in patients aged 75 years and older
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countries over time (except in Norway), incidence has 
increased (except for in Ireland and Australia; figure 2; 
appendix p 30).
Improvements in survival from stomach cancer were 
equally uniform across countries (table 2; appendix 
pp 11–12). Increases were more pronounced among 
patients younger than 75 years, and most notably in 
Ireland, where 5-year survival increased from 20% to 
33% over the 20-year period (table 3). All countries saw 
concurrent decreases in both incidence and mortality 
since 1995 (figure 2; appendix p 31).
5-year survival from colon cancer increased in all 
countries over 1995–2014 (table 2). The increases were 
greater in patients younger than 75 years than among 
those older than 75 years, with an at least 13 percentage 
point increase observed in Ireland, Denmark, and the 
UK (table 3). Although colon cancer mortality decreased 
across the study period in all countries, decreases in 
incidence were less pronounced and varied substantially 
by country (figure 2). Slight increases in incidence were 
observed in Norway, Denmark, and the UK (figure 2; 
appendix p 32).
Cancers of the rectum had the highest survival among 
the cancers studied, up to 90% for 1-year survival and 
71% for 5-year survival in 2010–14, both in Australia 
(appendix pp 11–12), with the most substantial increases 
in survival seen among patients younger than 75 years 
(table 3; appendix pp 13–14). Overall, 5-year rectal cancer 
survival increased substantially over the 1995–2014 
period, by more than 14 percentage points in Denmark, 
Ireland, and the UK. Considerable variations in incidence 
and mortality were seen across countries; although 
mortality decreased in all countries except Canada, 
incidence remained largely stable, except in Canada and 
Denmark, where incidence increased slightly (figure 2; 
appendix p 33).
Pancreatic cancer had the lowest survival among the 
studied cancer sites, although survival increases were 
observed over time in most countries except New Zealand 
(table 2; appendix pp 11–12). Slight increases in pancreatic 
cancer incidence were seen in all countries, although no 
appreciable changes were observed in mortality over 
time (figure 2; appendix p 34).
For lung cancer, although survival was highest in 
Canada, with a 5-year survival of 22% in 2010–14, survival 
increased most in Denmark, Ireland, and Norway, with a 
10–11 percentage point increase when comparing the 
periods 1995–99 with 2010–14 (table 2; appendix p 35). 
Survival was highest and showed the largest absolute 
increase in patients younger than 75 years, particularly in 
Denmark, Ireland, and Norway. Although survival 
improved for both sexes, incidence, and mortality varied 
by sex (appendix p 29); both incidence and mortality 
decreased in males, whereas in females incidence 
increased and mortality remained stable.
The highest 5-year survival for ovarian cancer was 
observed in Norway, followed by Australia and Denmark, 
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with survival ranging from 36% to 46% across countries 
for diagnoses in 2010–14 (table 2). Following considerable 
absolute improvements in survival over 1995–2014 across 
all countries, including Ireland and the UK, the most 
recent survival estimates in these countries, and in 
New Zealand, remained relatively low at around 36–37%. 
Decreases in both incidence and mortality were observed 
over the same time period in all countries (figure 2; 
appendix p 36).
All results are also available through the SURVMARK-2 
interactive online tool.
Discussion
This first ICBP SURVMARK-2 study has shown that 
cancer survival has continued to improve across 
seven high-income countries over the period 1995–2014. 
Compared with the first phase of ICBP, the number of 
cancer sites analysed has been expanded, including 
lung, colon, rectal, ovarian, oesophageal, stomach, and 
pancreatic cancer, and survival improve ments have been 
notable for cancers associated with worse prognoses and 
in patients diagnosed when younger than 75 years. 
Cancer survival was generally higher in Australia, 
Canada, and Norway. International differences narrowed 
across the study period for 1-year survival after diagnosis 
for all cancers except pancreatic cancer, whereas at 
5 years after diagnosis differences across countries 
only narrowed for oesophageal and rectal cancer. Our 
combined description of trends in incidence, mortality, 
and survival suggests substantial progress has been 
made in cancer control across these seven countries for 
stomach, colon, lung (in males), and ovarian cancer.
The uniform improvements in cancer survival in this 
study are probably the direct consequence of major health 
care reforms and technological advances that have 
enabled earlier diagnosis, more effective and tailored 
treatment, and better patient management than in 
previous periods. For example, rectal cancer had one of 
the most substantial increases in 5-year net survival over 
time, increasing between 9 and 21 percentage points in all 
seven countries. Improvements in surgical techniques, 
including the implementation of total mesorectal excision 
and new guidelines that include preoperative radiotherapy 
are among the key changes that have improved patient 
outcomes.17 Improvements in survival were largely seen 
among younger patients (aged <75 years) and might 
relate to the relatively wider access to adjuvant chemo-
therapy and ability of these patients to tolerate more 
aggressive treatments than older age groups. Addition-
ally, better diagnosis and staging with new technologies 
such as PET-CT imaging, alongside greater precision in 
the selection of patients for targeted therapies on the 
basis of molecular markers, have probably contributed. 
In Denmark, the substantial increases in survival seen 
across all cancers, particularly colorectal cancer, might 
have partly resulted from national health-care reforms 
in 2007 when cancer became regarded as an acute 
life-threatening disease, after which cancer-specific 
pathways for diagnosis and treatment were accelerated, 
including reduced waiting times in hospitals and large 
investments in radio therapy.18,19 International differences 
in access to diagnostic services, screening practices, 
treatments, patient pathways, and health-care systems, 
and their effect on survival are being further explored in 
ICBP studies.
Differences in coding and classification systems and 
cancer registration practices in different jurisdictions 
and countries are potential challenges to international 
population-based comparisons of cancer survival. Taking 
the example of staging—a principle determinant of cancer 
survival—the implementation of common recording 
systems has been hindered by variations in the availability 
of clinical information to determine the stage of cancer, 
the application of different staging guidelines, and 
differences in the pace of change in diagnostic and 
treatment practice.20 The validity of the definition of date 
of diagnosis, accuracy of ascertainment of death, and 
extent of trace-back of cases first notified by death 
certificates—eg. tracing notifications back to the source 
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Figure 2: Changes in age-standardised 5-year net survival against changes in mortality and incidence, 
2010–14 compared with 1995–99
Age-standardised net survival is for patients aged 15–99 years at diagnosis, and age-standardised incidence and 
mortality are for patients aged 25 years and older at diagnosis. Increases in survival paralleled by decreases in 
incidence and mortality are the optimum scenario and show true progress (green upper left quadrant). 
Other scenarios, such as increasing survival and decreasing mortality, accompanied by increasing incidence, 
point towards partial progress (red quadrants). Australia includes New South Wales (1995–2012), Victoria and 
Western Australia; Canada includes Alberta, British Columbia, Manitoba, New Brunswick, Nova Scotia, Ontario, 
and Saskatchewan; Ireland (1995–2013); the UK includes its four constituent countries: England, Scotland, Wales, 
and Northern Ireland; and all other countries with national data (1995–2014). Estimates for Prince Edward Island 
(Canada) are not shown because of large fluctuations in rates compared with the small number of cases.
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capable of confirming (or contradicting) the death cer-
tificate statement—are all possible source of artifacts that 
might vary by registry and differentially affect survival 
estimates.10,21,22 However, previous studies have shown that 
only an implausibly high level of missed cases or delayed 
(later or incorrectly assigned) dates of diagnosis would 
lead to a substantial effect on cancer survival estimates.21,23
Cancer registries included in ICBP SURVMARK-2 are 
covered by reasonably complete and efficient mortality 
measurement systems. Still, an earlier ICBP study10 has 
shown that local registration practices, including the 
prioritisation of earlier incidence dates and the exclusion 
of second or higher order tumours, might inflate survival 
and partly account for survival gaps between juris-
dictions. However, specific aspects of registration that 
might influence survival are uncollectable or beyond the 
control of the registry, such as the completeness of 
registration, characteristics of patients with cancer who 
are not included in the registries, and incomplete 
ascertainment of deaths. The individual and cumulative 
effect of these factors is extremely difficult, if not 
impossible, to measure. Insights into data collection 
processes and an in-depth assessment of coding, 
classification, and registration in collaboration with 
registry staff, biostatisticians, and clinicians are key to 
informing future strategies to improve international 
survival benchmarking.
The datasets assembled in this study are unique in 
several ways. ICBP SURVMARK-2 is based on a large 
international partnership that has facilitated the collation 
of 20 years of data from 21 longstanding cancer registries 
of internationally high quality. Stringent protocols for 
data processing and harmonisation were put in place 
and extensive exchanges with both registry staff and 
clinical advisors in each jurisdiction ensured optimal 
compar ability in the final datasets. The resulting survival 
estimates are analogous to those from previous inter-
national studies,2,4 although slight deviations might 
have occurred through differences in exclusion criteria 
and methodological approaches (eg, differences in the 
diagnostic window for period analyses and cancer 
definitions).
This study has several limitations. Although net sur-
vival is not subject to potential errors in cause of death 
certification, it remains a conceptual metric that is of 
little use to express the survival of an individual patient 
with cancer. Net survival is used at the population level to 
allow fair comparisons between countries and groups. 
Although we made every effort to ensure data com-
parability, differences in registration practices, and 
sources of information available to the individual 
registries might account for some of the variation in 
cancer survival seen across countries. Furthermore, the 
proportion of cases eligible for analysis varied by country 
and depended heavily on the proportion of cases of 
cancer determined by death certificate (or autopsy) only 
(varying between 2·3% and 4·8% for pancreatic cancer, 
and from 0·5% to 3·4% for the remaining cancer sites), 
and other quality control measures such as inconsis-
tencies between dates. In New Zealand, originally higher 
proportions of cases diagnosed by death certificate only 
can be linked to the 1994 Cancer Registry Act that 
mandated all laboratories to submit new diagnoses of 
cancer to the national registry. Because registrations 
were thus obtained from pathology, hospital discharge, 
or mortality sources, some clinically diagnosed cases not 
admitted to a hospital were notified to the registry via 
death certificates only after the patients had died. In this 
study, an additional assessment of inclusion of cases 
determined by death certificate only—under the extreme 
assumption that survival equalled 1 day—reduced the 
5-year survival estimates by a maximum of 0·6 percentage 
points in the most recent period. However, including 
cases diagnosed on the basis of death certificate or 
autopsy did not alter the overall patterns across countries 
and jurisdictions. Moreover, data from Canada and 
Australia were not national but covered most of their 
populations (76% of Canada’s population and 70% of 
Australia’s population), which is unlikely to restrict their 
representativeness. Different methods were applied to 
estimate survival in different time periods (cohort 
approach for patients diagnosed during 1995–2009, and 
period approach for diagnoses after 2010), which might 
affect the interpretation of trends.24 Finally, this study 
was not designed to assess the drivers of survival 
differences in-depth across countries or over time, but 
rather generate hypotheses that will be explored in future 
studies.
In summary, this first ICBP SURVMARK-2 study 
clearly shows that although cancer survival continues to 
improve across high-income countries, international 
disparities persist even for cancers with the worst 
prognoses. Earlier diagnosis, improved treatment, and 
other policy reforms have ensured improved pathways 
for patients to diagnosis and treatment and have all 
likely contributed to improved outcomes. Such progress 
in the control of the cancer types studied here, 
particularly cancers of the stomach, colon, lung 
(in males), and ovary, can be attributed to the delivery 
of multiple evidence-based and effective interventions 
that span the spectrum of cancer control, during the 
past two decades.
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